Circio invites to live webcast on 27 November 2026 at 10:00 am CET
* Circio management will provide an R&D and corporate update in a live webcast at 10:00am CET on Friday 27 November 2026 * The webcast will include a summary of Circio's ESGCT 2026 presentations and advances in heart gene therapy program, including the collaboration with Solid Biosciences * New data demonstrating in vivo proof-of-concept for circVec in next-generation AAV capsids will also be presented
Oslo, Norway, 20 November 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, will host a live webcast at 10:00am CET on Friday 27 November 2026.
In the webcast, CEO Dr. Erik D Wiklund will provide an overview of ongoing business development activities, including the recently announced collaboration with Solid Biosciences. CTO Dr. Thomas B Hansen will present the latest circVec pre-clinical gene therapy results, covering the heart program, new in vivo proof-of-concept data for circVec in next-generation AAV capsids and a summary of the oral presentation and two posters delivered at ESGCT 2026.
Presentation materials will be published ahead of the webcast on 27 November 2026.
The webcast will be held in English. Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast.
Time: 10:00 CET on Friday 27 November 2026
Click here to access Teams webcast (https://teams.microsoft.com/meet/3455191582554881?p=xH225uni4M13Nf8IP0) Meeting ID: 345 519 158 255 488 1 Passcode: g86R3cS9
A recording of the webcast will be made available on the Circio webpage (http://www.circio.com/) and the presentation materials are attached hereto.
For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com
Neil Hunter -- Hunter PR Phone: +44 782 125 5568 Email: neiljameshunter@gmail.com
About Circio Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 60-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.